A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma

Trial Profile

A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VESTRI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Aug 2016 Results from this trial will be presented at the European Respiratory Society (ERS) International Congress 2016, according to a GlaxoSmithKline plc media release.
    • 17 Mar 2016 Results published in the New England Journal of Medicine, according to a GlaxoSmithKline media release.
    • 17 Mar 2016 Primary endpoint (Time to first asthma exacerbation) has not been met, according to a GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top